Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Explore this paper's citation graph
Summary
Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
- Type
- article
- Published
- 1999-08-05
- Cited by
- 3,116
- References
- 37
- Access
- Open access
- OpenAlex
- https://openalex.org/W2328529137
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38607456
Keywords
Gemfibrozil, Medicine, Myocardial infarction, Internal medicine, Cholesterol
References
- Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
- The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification
- Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies.
- The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐up
- Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.
- Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
- Reverse cholesterol transport--a review of the process and its clinical implications.
- Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.
- The B-value: a tool for monitoring data.
- Prevalence of risk factors in men with premature coronary artery disease.
- Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.
- Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
- Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.
- Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
- The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study G
- Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
- Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins.
- Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial.
- Sample size determination in clinical trials with time-dependent rates of losses and noncompliance.
- Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group.
Cited by
- Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease.
- Current concepts in secondary prevention after acute myocardial infarction
- Trans fatty acids and plasma lipoproteins.
- Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.
- Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease.
- Lipid-lowering drugs in lupus: an unexplored therapeutic intervention
- Beyond the cholesterol profile: Monitoring therapeutic effectiveness of statin therapy
- Drugs for cardiovascular risk reduction in the diabetic patient
- Contemporary approaches for cardiovascular risk reduction in diabetes.
- The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis.
- Bedeutung der Lipidtherapie bei Diabetes
- Clinical Trials and Lipid Guidelines for Type II Diabetes
- Risk stratification for the prevention of cardiovascular complications of hypertension
- Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis
- Atherosclerotic Cardiovascular Disease Risk in the HAART-Treated HIV-1 Population
- Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
- Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
- High-density lipoprotein cholesterol therapies: the next frontier in lipid management.
- Cholesterol reduction yields clinical benefits: meta-analysis including recent trials.
- Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Related papers
- Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations.
- Immunochemical measurement of the vitamin D-binding protein in rat serum.
- Sex-specific effect of dietary cholesterol on plasma insulin and lipids of control and diabetic rats
- Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease.
- Hyperinsulinemia suppresses glucose utilization in specific brain regions: in vivo studies using the euglycemic clamp in the rat.
- Dose-dependent inhibition by ghrelin of insulin secretion in the mouse.
- Gene expression and serum thyroxine-binding globulin are regulated by adrenal status and corticosterone in the rat
- Gene expression and serum thyroxine-binding globulin are regulated by adrenal status and corticosterone in the rat.
- Glucose metabolism in experimental hyperthyroidism: intact in vivo sensitivity to insulin with abnormal binding and increased glucose turnover.
- Plasma leptin concentrations during extended fasting and graded glucose infusions: relationships with changes in glucose, insulin, and FFA.